References and Notes
<A NAME="RG12006ST-1A">1a</A>
Nakasawa HT.
Goon DJW.
Muldoon WP.
Zera RT.
J. Med. Chem.
1984,
27:
591
<A NAME="RG12006ST-1B">1b</A>
Samanen J.
Cash T.
Narindray D.
Brandeis E.
Adams W.
Weidemann H.
Yellin T.
J. Med. Chem.
1991,
34:
3036
<A NAME="RG12006ST-1C">1c</A>
Wonacott A.
Cooke R.
Hayes FR.
Hann MM.
Jhoti H.
McMeekin P.
Mistry A.
Murray-Rust P.
Singh OMP.
J. Med. Chem.
1993,
36:
3113
See, for example:
<A NAME="RG12006ST-2A">2a</A>
Chemistry and Biology of β-lactam Antibiotics
Vol. 1-3:
Morrin RB.
Gorman M.
Academic Press;
New York:
1982.
<A NAME="RG12006ST-2B">2b</A>
The Organic Chemistry of β-Lactams
George GI.
VCH;
New York:
1993.
<A NAME="RG12006ST-2C">2c</A>
The Chemistry of β-Lactams
Page MI.
Blackie Academic and Professional;
New York:
1996.
<A NAME="RG12006ST-3A">3a</A>
Walsh CT.
Science
2004,
303:
1805
<A NAME="RG12006ST-3B">3b</A>
Wöhr T.
Nahl F.
Nefzi A.
Rohwedder B.
Sato T.
Sun X.
Mutter M.
J. Am. Chem. Soc.
1996,
118:
9218
<A NAME="RG12006ST-3C">3c</A>
Botti P.
Pallin DT.
Tam JP.
J. Am. Chem. Soc.
1996,
118:
10018
<A NAME="RG12006ST-4">4</A>
Gandolfi CA.
Di Domenico R.
Spinelli S.
Gallico L.
Fiocchi L.
Lotto A.
Menta E.
Borghi A.
Dalla Rosa C.
Tognella S.
J. Med. Chem.
1995,
38:
508
<A NAME="RG12006ST-5A">5a</A>
Westland RD.
Lin MH.
Cooley RA.
Zwiesler ML.
Grenan MM.
J. Med. Chem.
1973,
16:
328
<A NAME="RG12006ST-5B">5b</A>
Farmer PS.
Leung C.-C.
Lui EMK.
J. Med. Chem.
1973,
16:
411
<A NAME="RG12006ST-5C">5c</A>
Wilmore BH.
Cassidy PB.
Warters RL.
Roberts JC.
J. Med. Chem.
2001,
44:
2661
<A NAME="RG12006ST-6">6</A>
Faury P.
Camplo M.
Charvet A.-S.
Mourier N.
Barthelemy P.
Graciet J.-C.
Kraus J.-L.
J. Heterocycl. Chem.
1994,
31:
1465
<A NAME="RG12006ST-7A">7a</A>
Engel W,
Schieberle P,
Guntert M, and
Lambrecht S. inventors; Eur. Patent 1069116.
; Chem. Abstr. 2001, 134, 85321
<A NAME="RG12006ST-7B">7b</A>
Schmidt CO.
Krammer GE.
Weber B.
Stoeckigt D.
Herbrand K.
Ott F.
Kindel G.
Brennecke S.
Gatfield IL.
Bertram H.-J.
Perfum. Flavor.
2005,
30:
28
<A NAME="RG12006ST-8">8</A>
Dubs O,
Kuentzel H,
Pesaro M, and
Schmidt H. inventors; Patentschrift (Switz.).
; Chem. Abstr. 1977, 87, 201514
<A NAME="RG12006ST-9A">9a</A>
Schneider PH.
Schrekker HS.
Silveira CC.
Wessjohann LA.
Braga AL.
Eur. J. Org. Chem.
2004,
2715
<A NAME="RG12006ST-9B">9b</A>
Cremonesi G.
Dalla Croce P.
Fontana F.
Forni A.
La Rosa C.
Tetrahedron: Asymmetry
2005,
16:
3371
<A NAME="RG12006ST-10A">10a</A>
Wang L.
Nakamura S.
Ito Y.
Toru T.
Tetrahedron: Asymmetry
2004,
15:
3059
<A NAME="RG12006ST-10B">10b</A>
Wang L.
Nakamura S.
Toru T.
Org. Biomol. Chem.
2004,
2:
2169
<A NAME="RG12006ST-11">11</A>
Gawley RE.
Zhang Q.
McPhail AT.
Tetrahedron: Asymmetry
2000,
11:
2093
<A NAME="RG12006ST-12">12</A> Meyers A. I., Edwards P. D., Rieker W. F., Bailey T. R.; J. Am. Chem. Soc.; 1984, 106: 3270
<A NAME="RG12006ST-13A">13a</A>
Degl’Innocenti A.
Capperucci A.
Nocentini T.
Tetrahedron Lett.
2001,
42:
4557
<A NAME="RG12006ST-13B">13b</A>
Capperucci A.
Ceré V.
Degl’Innocenti A.
Nocentini T.
Pollicino S.
Synlett
2002,
1447
<A NAME="RG12006ST-14">14</A>
Capperucci A.
Degl’Innocenti A.
Nocentini T.
Mordini A.
Biondi S.
Dini F.
Lett. Org. Chem.
2004,
1:
55
<A NAME="RG12006ST-15">15</A>
Typical Procedure: A solution of thiazolidine (1, 50 mg, 0.17 mmol), benzaldehyde (2a, 36 mg, 0.34 mmol) and activated MS (4 Å, 300 mg) was stirred at r.t. in freshly
distilled THF (3 mL) under an inert atmosphere. TBAF (68 mL of a 1 M THF solution,
0.07 mmol) was added dropwise (0.2 equiv every hour). The mixture was stirred at r.t.
and progression of the reaction was monitored by TLC. The reaction was quenched with
H2O and the product was extracted into Et2O (2 mL). The resulting organic layer was washed with brine, dried over Na2SO4 and the solvent evaporated under vacuum. Purification using column chromatography
(hexane-EtOAc, 4:1) afforded 13 mg (34%) of anti-3a and 13 mg (34%) of syn-3a. anti-3a: 1H NMR (200 MHz, CDCl3): δ = 3.04-3.15 (m, 2 H), 4.42-4.53 (m, 2 H), 4.99 (d, J = 1.8 Hz, 1 H), 5.52 (d, J = 1.8 Hz, 1 H), 7.36-7.42 (m, 5 H); 13C NMR (50 MHz, CDCl3): δ = 30.5, 40.5, 72.0, 79.9, 127.2, 127.4, 128.1, 138.3, 157.4; MS: m/z (%) = 221 (49) [M+], 130 (32), 115 (55), 91 (100), 87 (90), 77 (34). syn-3a: 1H NMR (200 MHz, CDCl3): δ = 2.90-3.01 (m, 2 H), 3.10-3.25 (m, 1 H), 4.36-4.44 (m, 1 H), 5.41 (d, J = 5.8 Hz, 1 H), 5.92 (d, J = 5.8 Hz, 1 H), 7.20-7.45 (m, 5 H). 13C NMR (50 MHz, CDCl3): δ = 30.3, 41.5, 69.9, 81.2, 127.2, 127.6, 128.3, 138.6, 157.4. MS: m/z (%) = 221 (31) [M+], 130 (36), 115 (39), 91 (100), 87 (78), 77 (38).
<A NAME="RG12006ST-16">16</A>
Variable amounts of benzyloxytrimethylsilane were detected in the reactions affording
cyclic compounds 3. However, we were unable to detect silylated derivatives of 5 even before work-up, either under TLC or GC/MS conditions.
<A NAME="RG12006ST-17">17</A>
Characterization of Compounds 3g and 5g: diastereomers were separated by preparative TLC (silica gel, hexane-EtOAc, 4:1).
7-(Thiophen-2-yl)tetrahydroxooxazolo[4,3-
b
]thiazol-5-one (
3g): (anti-3g): 1H NMR (200 MHz, CDCl3): δ = 2.95-3.10 (m, 2 H), 4.40-4.50 (m, 2 H), 5.14 (d, J = 1.6 Hz,1 H), 5.74 (d, J = 1.6 Hz, 1 H), 7.00-7.10 (m, 1 H), 7.14-7.20 (m, 1 H), 7.28-7.40 (m, 1 H); 13C NMR (50 MHz, CDCl3): δ = 31.8, 49.4, 71.3, 78.1, 126.8, 127.0, 127.1, 146.1, 157.6; MS: m/z (%) = 227 (74) [M+], 183 (19), 136 (33), 128 (29), 127 (47) 115 (50), 97 (26), 91 (40), 87 (100), 60
(59). (syn-3g): 1H NMR (200 MHz, CDCl3): δ = 2.95-3.10 (m, 2 H), 4.40-4.50 (m, 2 H), 5.36 (d, J = 5.6 Hz, 1 H), 6.10 (d, J = 5.6 Hz, 1 H), 7.00-7.10 (m, 1 H), 7.14-7.20 (m, 1 H), 7.28-7.40 (m, 1 H); 13C NMR (50 MHz, CDCl3): δ = 31.3, 49.7, 71.5, 77.8, 126.6, 126.8, 127.0, 145.6, 157.6; MS: m/z (%) = 227 (8) [M+], 149 (26), 111 (54), 97 (38), 91 (100), 71 (55). 1-[2-(Hydroxy(thiophen-2-yl)methyl]thiazolidin-3-yl)-2-phenylethanone (
5g): (anti-5g): 1H NMR (200 MHz, CDCl3): δ = 2.50-2.70 (m, 1 H), 2.70-2.90 (m, 1 H), 3.20-3.50 (m, 1 H), 3.95-4.20 (m, 1
H), 5.15 (d, J = 6.6 Hz, 1 H), 5.19 (m, 2 H), 5.44 (d, J = 6.6 Hz, 1 H), 7.00-7.10 (m, 1 H), 7.14-7.30 (m, 2 H), 7.32-7.45 (m, 5 H); 13C NMR (50 MHz, CDCl3): δ = 31.3, 49.4, 68.0, 71.5, 74.5, 125.7, 126.6, 127.0, 128.1, 128.3, 128.6, 135.0,
151.1. (syn-5g): 1H NMR (200 MHz, CDCl3): δ = 2.50-2.70 (m, 1 H), 2.70-2.90 (m, 1 H), 3.79-3.91 (m, 1 H), 4.20-4.35 (m, 1
H), 5.19 (m, 2 H), 5.29 (br s, 1 H), 5.52 (br s, 1 H), 7.00-7.10 (m, 1 H), 7.14-7.32
(m, 2 H), 7.33-7.46 (m, 5 H).
<A NAME="RG12006ST-18">18</A>
anti
-Benzyl 2-[hydroxy(phenyl)methyl]thiazolidine-3-carboxylate (anti-5a): 1H NMR (200 MHz,CDCl3): δ = 2.38-2.60 (m, 1 H), 2.61-2.80 (m, 1 H), 3.10-3.40 (m, 1 H), 3.92-4.19 (m, 1
H), 4.87 (d, J = 6.6 Hz, 1 H), 5.16 (m, 2 H), 5.45 (d, J = 6.6 Hz, 1 H), 7.18-7.45 (m, 10 H); 13C NMR (50 MHz, CDCl3): δ = 30. 5, 49.4, 68.0, 71.6, 79.0, 125.5, 127.3, 128.2, 128.4, 134.9, 136.0, 150.9.
<A NAME="RG12006ST-19">19</A>
A referee suggested that one equivalent of fluoride is necessary for total reaction
with benzaldehydes substituted with an electron-withdrawing group because there may
be an ineffective TMS transfer in these cases. In this event a classical nucleophilic
reaction involving the complete desilylation by fluoride would operate.